Clinical trial
5-Alpha Reductase and Anabolic Effects of Testosterone
NCT00475501 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00475501 |
|---|---|
| Title | 5-Alpha Reductase and Anabolic Effects of Testosterone |
| Official title | 5-Alpha Reductase and Anabolic Effects of Testosterone |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Collaborators | Endo Pharmaceuticals Industry Merck Sharp & Dohme LLC |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy |
| Intervention type | Drug, Other |
| Interventions | Testosterone Enanthate, Finasteride, Placebo |
| Enrollment | 60 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2012 |
| Completion | Oct 1, 2014 |
| First posted | May 21, 2007 |
| Last update posted | Oct 11, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: